[go: up one dir, main page]

DE60111574D1 - Bisphosphonate-enthaltenden zusammensetzungen zur vorbeugung und/oder heilung von metabolischen knochenkrankheiten, verfahren zu ihren herstellung und benutzung dieser zusammensetzungen - Google Patents

Bisphosphonate-enthaltenden zusammensetzungen zur vorbeugung und/oder heilung von metabolischen knochenkrankheiten, verfahren zu ihren herstellung und benutzung dieser zusammensetzungen

Info

Publication number
DE60111574D1
DE60111574D1 DE60111574T DE60111574T DE60111574D1 DE 60111574 D1 DE60111574 D1 DE 60111574D1 DE 60111574 T DE60111574 T DE 60111574T DE 60111574 T DE60111574 T DE 60111574T DE 60111574 D1 DE60111574 D1 DE 60111574D1
Authority
DE
Germany
Prior art keywords
compositions
bisphosphonate
healing
prevention
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60111574T
Other languages
English (en)
Other versions
DE60111574T2 (de
Inventor
Daniel Zanetti
Damian Cairatti
Enrique Piccinni
J Roldan
Socrates Papapoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gador SA
Universiteit Leiden
Original Assignee
Gador SA
Universiteit Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gador SA, Universiteit Leiden filed Critical Gador SA
Application granted granted Critical
Publication of DE60111574D1 publication Critical patent/DE60111574D1/de
Publication of DE60111574T2 publication Critical patent/DE60111574T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3843—Polyphosphonic acids containing no further substituents than -PO3H2 groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3856—Polyphosphonic acids containing halogen or nitro(so) substituents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/386—Polyphosphonic acids containing hydroxy substituents in the hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60111574T 2001-01-23 2001-01-23 Bisphosphonate enthaltende Zusammensetzungen zur Vorbeugung und/oder Heilung von metabolischen Knochenkrankheiten, Verfahren zu ihrer Herstellung und Benutzung dieser Zusammensetzungen Expired - Lifetime DE60111574T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2001/000690 WO2002058708A1 (en) 2001-01-23 2001-01-23 Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof

Publications (2)

Publication Number Publication Date
DE60111574D1 true DE60111574D1 (de) 2005-07-21
DE60111574T2 DE60111574T2 (de) 2006-05-11

Family

ID=8164260

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60111574T Expired - Lifetime DE60111574T2 (de) 2001-01-23 2001-01-23 Bisphosphonate enthaltende Zusammensetzungen zur Vorbeugung und/oder Heilung von metabolischen Knochenkrankheiten, Verfahren zu ihrer Herstellung und Benutzung dieser Zusammensetzungen

Country Status (13)

Country Link
US (2) US7560490B2 (de)
EP (1) EP1372669B1 (de)
JP (1) JP2004519463A (de)
KR (1) KR100593510B1 (de)
AR (1) AR047480A1 (de)
AT (1) ATE297740T1 (de)
BR (1) BRPI0116865B8 (de)
CA (1) CA2431515C (de)
DE (1) DE60111574T2 (de)
DK (1) DK1372669T3 (de)
ES (1) ES2243457T3 (de)
MX (1) MXPA03006565A (de)
WO (1) WO2002058708A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03006565A (es) * 2001-01-23 2005-07-29 Gador Sa Composicion comprendiendo bisfosfonatos para la prevencion y/o tratamiento de enfermedades metabolicas de huesos, proceso para preparar tal composicion y el uso de la misma.
RU2294203C2 (ru) * 2001-12-21 2007-02-27 Дзе Проктер Энд Гэмбл Компани Способ лечения костных нарушений
KR20120065435A (ko) * 2002-05-10 2012-06-20 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
JP4427453B2 (ja) * 2002-12-20 2010-03-10 エフ．ホフマン−ラ ロシュ アーゲー 高用量イバンドロネート製剤
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
ES2361333T3 (es) * 2006-09-04 2011-06-16 Gador S.A. Composición líquida para la prevención y/o el tratamiento de diferentes enfermedades metabólicas óseas, usos de la misma, y procedimiento para la preparación de la misma.
EP2240159A2 (de) * 2008-02-05 2010-10-20 Actavis Group PTC EHF Formulierungen von alendronat, herstellungs- und anwendungsverfahren dafür
FI20115315A0 (fi) * 2011-04-01 2011-04-01 Itae Suomen Yliopisto Menetelmä metallien keräämiseksi
CN105410940B (zh) * 2015-12-27 2018-08-24 山东阜丰发酵有限公司 一种包含黄原胶的保健食品

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
US4313765A (en) * 1980-09-24 1982-02-02 Merck & Co., Inc. Synergistic blends of cellulase-free xanthan gum and cellulosics
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
US4788220A (en) * 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
FR2629716B1 (fr) * 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
FI89364C (fi) * 1990-12-20 1993-09-27 Leiras Oy Foerfarande foer framstaellning av nya, farmakologiskt anvaendbara metylenbisfosfonsyraderivat
ATE195075T1 (de) * 1991-11-22 2000-08-15 Procter & Gamble Pharma Risedronat enthaltende arzneimittel mit verzögerter wirkstoffabgabe
TW237386B (de) * 1992-04-15 1995-01-01 Ciba Geigy
JP3332426B2 (ja) * 1992-10-02 2002-10-07 太田製薬株式会社 大腸および小腸の検査用ｘ線造影剤
CN1089583C (zh) * 1993-10-01 2002-08-28 辛泰克斯（美国）公司 霉酚酸2－(4－吗啉代)乙酯高剂量口服悬浮剂
US5674522A (en) * 1993-10-07 1997-10-07 Mcneil-Ppc, Inc. Beverage concentrate for drug delivery
CA2173333A1 (en) * 1993-10-19 1995-04-27 Barry J. Gertz Combination of bisphosphonates and growth hormone secretagogues
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
UA41909C2 (uk) * 1994-07-22 2001-10-15 Елі Ліллі Енд Компані Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
AR000555A1 (es) * 1994-12-28 1997-07-10 Gador Sa Uso de composiciones anabolicas para la masa osea en base a cantidades efectivas no toxicas del ácido Ä3-(n,n-dimetilamino)-1-hidroxipropilidenoÜbisfosfonico o la sal monosodica u otra sal farmacéuticamente aceptable del mismo
JPH08333245A (ja) * 1995-06-07 1996-12-17 Taisho Pharmaceut Co Ltd イブプロフェン懸濁液剤
TW442287B (en) * 1995-06-13 2001-06-23 American Home Produits Corp Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac)
PL332496A1 (en) * 1996-10-04 1999-09-13 Merck & Co Inc Liquid alendronate preparations
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
GB9815532D0 (en) * 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
CO5160260A1 (es) * 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
WO2000074685A1 (fr) * 1999-06-02 2000-12-14 Sumitomo Pharmaceuticals Co., Ltd. Preparations orales d'etidronate disodique
US20020002169A1 (en) * 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
AU2002231721A1 (en) * 2000-12-18 2002-07-01 Societe Des Produits Nestle S.A. Stabilizer based on microcrystalline cellulose for drink and dressing formulations
MXPA03006565A (es) * 2001-01-23 2005-07-29 Gador Sa Composicion comprendiendo bisfosfonatos para la prevencion y/o tratamiento de enfermedades metabolicas de huesos, proceso para preparar tal composicion y el uso de la misma.

Also Published As

Publication number Publication date
ATE297740T1 (de) 2005-07-15
AR047480A1 (es) 2006-01-25
US8853187B2 (en) 2014-10-07
DE60111574T2 (de) 2006-05-11
CA2431515A1 (en) 2002-08-01
US20090247491A1 (en) 2009-10-01
DK1372669T3 (da) 2005-10-17
EP1372669B1 (de) 2005-06-15
BR0116865B1 (pt) 2014-03-11
JP2004519463A (ja) 2004-07-02
US7560490B2 (en) 2009-07-14
KR20030086988A (ko) 2003-11-12
BRPI0116865B8 (pt) 2021-05-25
ES2243457T3 (es) 2005-12-01
CA2431515C (en) 2008-01-22
MXPA03006565A (es) 2005-07-29
KR100593510B1 (ko) 2006-06-28
US20040087550A1 (en) 2004-05-06
BR0116865A (pt) 2004-02-25
EP1372669A1 (de) 2004-01-02
WO2002058708A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
DE60301350D1 (de) Verfahren zur herstellung von 7-substituierten -3-chinolin und 3-chinol-4-on carbonitrile
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
ATE381347T1 (de) Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
EP1651164A4 (de) Zusammensetzung und verfahren zur behandlung von neurologischen erkrankungen
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
ATE395871T1 (de) Marknagel zur behandlung von proximalen oberschenkelknochenbrüchen
DE60238576D1 (de) Zusammensetzung zur Herstellung von Elektroden und Elektroden
EP1534074A4 (de) Kombinationstherapie zur behandlung von fettleibigkeit
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
EP1432310A4 (de) Verfahren zur behandlung von chronischem herzversagen und/oder erhöhtem cholesterinspiegel mittels 3,5-diiodthyropropionsäure, sowie verfahren zu ihrer herstellung
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
DE60111574D1 (de) Bisphosphonate-enthaltenden zusammensetzungen zur vorbeugung und/oder heilung von metabolischen knochenkrankheiten, verfahren zu ihren herstellung und benutzung dieser zusammensetzungen
DE60203299D1 (de) Fungizide zusammensetzung und verwendung dieser zusammensetzung zur bekämpfung von pflanzenkrankheiten
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
DE50014819D1 (de) Profilkörper zur herstellung von sportgeräten und verfahren zur herstellung des profilkörpers
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
DE60327856D1 (de) Zusammensetzungen und verfahren zur hautbräunung
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
EP1575497A4 (de) Neue zusammensetzung und verfahren zur behandlung von psoriasis
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
DE60216457D1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition